Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

NCT03356782 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT03356782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03356782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 1, 2027
Completion date
December 31, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, osteoid sarcoma, sarcoma